SUMO1, human recombinant

Alternate Names / Synonyms: Small ubiquitin-related modifier 1, SUMO-1, Sentrin, Ubiquitin-like protein SMT3C, SMT3 homolog 3, Ubiquitin-homology domain protein PIC1, Ubiquitin-like protein UBL1, GAP-modifying protein 1, GMP1, SUMO1, SMT3C, SMT3H3, UBL1, PIC1, SMT3, DAP-1, OFC10, SENP2.

Gene Symbol: SUMO1

Accession #: P63165

Gene ID: 7341

Gene Source: Human

Recombinant Host: E. coli

Appearance: Liquid

Physical Form: In 50 mM HEPES, pH 8.0, plus 150 mM NaCl, 1 mM DTT.

Molecular Weight: 11.1 kDa

Purity by SDS-PAGE: ≥90%

Purity by HPLC: N/A

Endotoxin Level: <0.1 ng/μg

Biological Activity: Typical in vitro concentrations for conjμgate formation is 10-50 µM depending on conditions.

Reconstitution: N/A

Storage Temp.: -80°C

Shipping: Blue ice

Background Information: SUMO modification has been implicated in functions such as nuclear transport, chromosome segregation and transcriptional regulation. SUMO1 functions in a manner similar to ubiquitin in that it is bound to target proteins as part of a post-translational modification system. Still, unlike ubiquitin which targets proteins for degradation, SUMO1 is involved in a variety of Cellular processes, for example nuclear transport, transcriptional regulation, apoptosis, and protein stability. SUMO1 is not active until the last four amino acids of the carboxy-terminus are cleaved off. The active recombinant SUMO-1 protein is derived from the precursor pro-SUMO-1 (Accession # NM_003352). Human SUMO-1 shares 46% and 47% identity with SUMO-2 and SUMO-3 respectively. SUMOylation can occur without the requirement of a specific E3 ligase activity, where SUMO is transferred directly from UbcH9 to specific substrates. SUMOylated substrates are primarily localized to the nucleus (RanGAP-1, RANBP2, PML, p53, Sp100, HIPK2) but there are also cytosolic substrates (IκBα, GLUT1, GLUT4).

Handling: Centrifuge the vial prior to opening.